Outsourcing of API synthesis has stabilized in the decade since Rohner Chem entered the pharma sector in earnest, and according to CEO Daniel Pedrett the company has reached a position where it is faster, more agile and more experienced than the internal supply organizations of many mid-sized innovators.
You were brought into Rohner Chem in 2006 – what have been some of the fundamental changes to for the business since that time?
Rohner Chem has more than 100 years of history in the chemical business, with a strong presence in the dye stuff, and had been operated under Ciba Geigy for a number of years.
The first challenge was to transform RohnerChem from a production site and part of a larger conglomerate into an efficient, independent company.
"In general, our focus is to work with customers developing new drugs, and we usually begin the collaboration around phase II. At this stage the synthesis route has been well defined by the client or a CRO they’ve already engaged, and our responsibility is to manage the scale-up process and then manufacture at the commercial scale when and if the product is approved."
